Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00126425 · ClinicalTrials.gov registry record · Phase 3
Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease
A Phase 3 study, sponsored by GE Healthcare.
- Completed
- Registry status
- Phase 3
- Development phase
- 587
- Enrollment target
NCT00126425: Completed Phase 3 study, sponsored by GE Healthcare.
NCT00126425 is a Phase 3 study that has completed, run by GE Healthcare. The registered enrollment target is 587 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (24% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00126425, a Phase 3 study, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 587 participants
- Enrollment target
Study Summary
The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcomes in subjects with heart failure and in comparison to subjects without cardiovascular disease.
Primary Outcome
H/M ratio for 123I-mIBG uptake at 3 hours 50 minutes post administration was calculated by dividing the counts/pixel in the total myocardium region of interest (ROI) by the counts/pixel in the 7x7 pixel mediastinal ROI. Assessments were done by 3 independent readers. H/M ratios were categorized as 'Low' and 'High' based on being \<1.6 or ≥1.6 respectively. The efficacy of 123I-mIBG was based on the prognostic value of the imaging data collected relative to time to adverse cardiac events.
Interventions
- DRUG 123I-mIBG (meta-iodobenzylguanidine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 587 participants |
| Start Date | 2005-07 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
What the finished NCT00126425 record still lists
NCT00126425 is an interventional study that assigns participants to a tested intervention. The registered 587 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (24% lower).
The record links to 0 conditions, and to 1 intervention - of which 123I-mIBG (meta-iodobenzylguanidine) is the first listed.
NCT00126425 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00126425 about?
NCT00126425 is a clinical study titled "Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease". The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcomes in subjects with heart failure and in comparison to subjects without cardiovascular disease.
What is the current status of trial NCT00126425?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 587 participants. The study started on 2005-07. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00126425?
The interventions under investigation include: 123I-mIBG (meta-iodobenzylguanidine) (DRUG).
Who is sponsoring clinical trial NCT00126425?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00126425's enrollment target sits among peer trials
587 645th of 2000 higher than 1,354 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06921603 · 588 participants · NA
POCUS-Guided Diuresis for Decompensated Heart Failure
- NCT06986954 · 588 participants
Beacon Tip Sizing Catheter and Slip-Cath Beacon Tip Catheter Study
- NCT04134260 · 586 participants · Phase 3
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
- NCT06100770 · 586 participants
Aveir AR Coverage With Evidence Development (CED) Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia